G. Cortesina et al., Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases, INT J CANC, 89(3), 2000, pp. 286-292
In head and neck squamous cell carcinomas (HNSCC), metastasis to cervical l
ymph nodes is a major determinant of patient outcome. To detect metastases,
we used the MET oncogene as marker, which encodes the receptor for hepatoc
yte growth factor/scatter factor, mediating epithelial cell motility and in
vasiveness, The MET gene is expressed in epithelia and over-expressed in ca
rcinomas of specific histotypes, but not in lymphatic tissue. A total of 15
1 lymph nodes from 20 squamous cell carcinomas were studied with both in-de
pth histology and end-point and real-time quantitative RT-PCR. MET-encoded
sequences were found in 61 of 151 nodes (40%), of which 24 (16%) were found
metastatic by in-depth histopathology. parallel routine histopathologic an
alysis of 654 lymph nodes from the same cases identified 36 metastases (5%)
, Real-time quantitative RT-PCR was used to measure MET gene-specific mRNA
in normal tissues, primary tumors and lymphatic metastases and showed a 2-8
-fold increased expression in tumor cells which metastasize. RT-PCR for 3 c
ytokeratins expressed in HNSCC (K4, K10 and K13) proved to be less sensitiv
e in detecting occult lymphatic metastases, Western blot analysis demonstra
ted the presence of the full-size MET receptor in primary tumors and lymph
node metastases; immunohistochemistry showed receptor localization in tumor
cells. Altogether, these data demonstrate that the MET gene product is a v
aluable marker with which to detect occult tumor cells in lymph nodes, than
ks to its high expression in metastatic cells. After RT-PCR analysis we wer
e able to attribute a move advanced stage to 10 out of 20 HNSCC cases, incl
uding 5 cases classified as tumor-free after routine histopathology. (C) 20
00 Wiley-Liss, Inc.